• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Infect Dis . COVID-19 breakthrough infection and post-vaccination neutralizing antibody among healthcare workers in a referral hospital in Toky

tetano

Editor, Senior Moderator
Clin Infect Dis


. 2021 Dec 24;ciab1048.
doi: 10.1093/cid/ciab1048. Online ahead of print.
COVID-19 breakthrough infection and post-vaccination neutralizing antibody among healthcare workers in a referral hospital in Tokyo: a case-control matching study


Shohei Yamamoto[SUP] 1 [/SUP], Kenji Maeda[SUP] 2 [/SUP], Kouki Matsuda[SUP] 2 [/SUP], Akihito Tanaka[SUP] 3 [/SUP], Kumi Horii[SUP] 4 [/SUP], Kaori Okudera[SUP] 5 [/SUP], Junko S Takeuchi[SUP] 6 [/SUP], Tetsuya Mizoue[SUP] 1 [/SUP], Maki Konishi[SUP] 1 [/SUP], Mitsuru Ozeki[SUP] 3 [/SUP], Haruhito Sugiyama[SUP] 7 [/SUP], Nobuyoshi Aoyanagi[SUP] 8 [/SUP], Hiroaki Mitsuya[SUP] 2 [/SUP], Wataru Sugiura[SUP] 9 [/SUP], Norio Ohmagari[SUP] 10 [/SUP]



Affiliations

Abstract

Background: While increasing coverage of effective vaccines against coronavirus disease 2019 (COVID-19), emergent variants raise concerns about breakthrough infection. Data are limited, however, whether breakthrough infection during the epidemic of the variant is ascribed to insufficient vaccine-induced immunogenicity.
Methods: We described incident COVID-19 in relation to the vaccination program among workers of a referral hospital in Tokyo. During the predominantly Delta epidemic, we followed 2,415 fully vaccinated staff (BNT162b2) for breakthrough infection and selected three matched controls. We measured post-vaccination neutralizing antibodies against the wild-type, Alpha (B.1.1.7), and Delta (B.1.617.2) strains using live viruses and anti-spike antibodies using quantitative assays, and compared them using the generalized estimating equation model between the two groups.
Results: No COVID-19 cases occurred 1-2 months after the vaccination program during the fourth epidemic wave in Japan, dominated by the Alpha variant, while 22 cases emerged 2-4 months after the vaccination program during the fifth wave, dominated by the Delta variant. In the vaccinated cohort, all 17 cases of breakthrough infection were mild or asymptomatic and had returned to work early. There was no measurable difference between cases and controls in post-vaccination neutralizing antibody titers against the wild-type, Alpha, and Delta, and anti-spike antibody titers, while neutralizing titers against the variants were considerably lower than those against the wild-type.
Conclusions: Post-vaccination neutralizing antibody titers were not decreased among patients with breakthrough infection relative to their controls under the Delta variant rampage. The result points to the importance of infection control measures in the post-vaccination era, irrespective of immunogenicity profile.

Keywords: COVID-19; breakthrough infection; neutralizing antibody; vaccination.
 
Back
Top Bottom